Latest:
Dr Lonial on the Impact of the CoMMpass Study on Personalized Medicine in Multiple Myeloma
Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Sagar Lonial, MD, FACP
Latest:
Dr Lonial on the Outcomes of the IKEMA Trial in Relapsed Multiple Myeloma
Sagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.
Sagar Lonial, MD, FACP, Winship Cancer Institute
Latest:
Investigational Agents for Relapsed/Refractory Myeloma
Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Sagus Sampath, MD
Sagus Sampath, MD, is an associate clinical professor and medical director of the Department of Radiation Oncology at City of Hope in Duarte, California
Latest:
Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress
Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.
Sai-Hong I. Ou, MD
Latest:
Dr. Ou on the Use of Crizotinib in Patients With ROS1-Rearranged NSCLC
Sai-Hong I. Ou, MD, professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, discusses the use of crizotinib (Xalkori) in the treatment of patients with ROS1-rearranged non–small cell lung cancer (NSCLC).
Sai-Hong I. Ou, MD, PhD
Latest:
Dr. Ou on the FDA Approval of Pembrolizumab in SCLC
Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses the FDA approval of pembrolizumab (Keytruda) in small cell lung cancer (SCLC).
Sai-Hong Ignatius Ou, MD, PhD
Latest:
Dr. Ou on Alectinib as Treatment for NSCLC
Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.
Sairah Ahmed, MD
Sairah Ahmed, MD, is an associate professor in the Department of Lymphoma/Myeloma, of the Division of Cancer Medicine, and director of the CAR T Program at The University of Texas MD Anderson Cancer Center.
Latest:
Efficacy and Safety Data for CAR T Therapies in Marginal Zone Lymphoma
Panelists discuss how emerging evidence supports the use of CAR T therapy for patients with relapsed or refractory marginal zone lymphoma.